Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of [●] ("Holder"), as registered owner of this Purchase Warrant, to Tenon Medical, Inc., a Delaware corporation (the "Company"), Holder is entitled, at any time or from time to time beginning [●], 2022 (the "Commencement Date"), and at or before 5:00 p.m., Eastern time, [●], 2026 (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the
...Company, par value $0.00001 per share (the "Shares"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context.
View More
Purchase Warrant. THIS CERTIFIES THAT,
in consideration pursuant to that certain Underwriting Agreement by and between., FOTV Media Networks Inc., a Delaware corporation (the "Company") and Monarch Bay Securities, LLC ("MBS"), as Representative of
funds duly paid by the several underwriters, dated August [•], 2016 (the "Underwriting Agreement"), MBS (in such capacity with its permitted successors or
on behalf of [●] ("Holder"), assigns, the "Holder"), as registered owner of this Purchase Warrant,
to Tenon Medical..., Inc., a Delaware corporation (the "Company"), Holder is entitled, at any time or from time to time beginning [●], 2022 from [•], 2017 (the "Commencement Date"), "Exercise Date") [THE DATE THAT IS 180 DAYS AFTER THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT], and at or before 5:00 p.m., Eastern time, [●], 2026 [•], 2021 [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING] (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] [•] shares of common stock of the Company, par value $0.00001 $0.001 per share (the "Shares"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] $[•] per Share; Share (125.0% of the price of the Shares sold in the Offering); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.
View More
Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of
[●] __________ ("Holder"), as registered owner of this
Common Stock Purchase
Warrant, Warrant (this "Purchase Warrant"), to
Tenon Medical, Acurx Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Holder is entitled, at any time or from time to time
beginning [●], 2022 from ___, [DATE THAT IS 180 DAYS FROM THE EFFECTIVE DATE OF THE OFFERING] (the "Commencement Date"), and at or before 5:00 p.m., Eastern time,
...[●], 2026 ____, 202__ [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING] (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares (the "Shares") of common stock of the Company, par value $0.00001 $0.001 per share (the "Shares"), "Common Stock"), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] $__ per Share; Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Purchase Warrant is being issued pursuant to the certain Underwriting Agreement (the "Underwriting Agreement"), dated ___, 2021, by and among the Company, the Representative and other underwriters named therein, providing for the public offering (the "Offering") of shares of Common Stock. The term "Effective Date" shall mean the effective date of the Registration Statement on Form S-1 (File No. 333-___). The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context. Initially capitalized terms not otherwise defined herein shall have the meanings given to those terms in the Underwriting Agreement.
View More
Purchase Warrant. THIS CERTIFIES THAT,
in consideration of funds duly paid pursuant to that certain Placement Agency Agreement by
and between ADOMANI, Inc., a Delaware corporation (the "Company"), and Boustead Securities, LLC ("Boustead"), as placement agent, dated January 5, 2018 (the "Placement Agency Agreement"), Boustead (in such capacity with its permitted successors or
on behalf of [●] ("Holder"), assigns, the "Holder"), as registered owner of this Purchase Warrant,
to Tenon Medical, Inc., a Delaware corpor...ation (the "Company"), Holder is entitled, at any time or from time to time beginning from [●], 2022 20[__] (the "Commencement Date"), "Exercise Date") [THE DATE THAT IS 180 DAYS AFTER THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT], and at or before 5:00 p.m., Eastern time, [●], 2026 20[ ] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING] (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.00001 per share (the "Shares"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] per Share; Share [125.0% of the price of the Units sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Placement Agency Agreement.
View More
Purchase Warrant. THIS CERTIFIES THAT,
in consideration of funds duly paid pursuant to that certain Underwriting Agreement by
or and between ADAMAS ONE CORP., a Nevada corporation (the "Company"), on
behalf of one hand, and Alexander Capital, L.P., on the other hand, dated [●], 2022, as amended (the "Underwriting Agreement"), [●]
("Holder"), ("Holder") and its assignees, as registered
owner holders of this Purchase Warrant,
to Tenon Medical, Inc., a Delaware corporation (the "Company"), Holder is entitled, at any
... time or from time to time beginning from [●], 2022 202[●] (the "Commencement "Exercise Date"), the date that is six (6) months after the effective date of the Company's Registration Statement on Form S-1 with the Securities and Exchange Commission (the "Effective Date"), and at or before 5:00 p.m., Eastern time, on [●], 2026 202[●] (five (5) years from the Effective Date) (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock Common Stock of the Company, $0.001 par value $0.00001 per share (the "Shares"), "Common Stock") (equal to six (6.0%) percent of the Common Stock sold in the offering), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. purchase warrant ("Purchase Warrant"). This Purchase Warrant is initially exercisable at $[●] per Share; share of Common Stock (125% of the price of the Common Stock sold in the Offering); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share share and the number of Shares shares of Common Stock to be received upon such exercise, shall be adjusted as therein specified. The term "Exercise Price" shall mean the initial exercise price as set forth above or the adjusted exercise price, price as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement. 1A date that is five years after the Effective Date of this Warrant.
View More
Purchase Warrant. THIS CERTIFIES THAT,
for value received by Matthew B. Proman ("Holder") in consideration of
funds duly paid the Merger Agreement dated July 11, 2014 by
or on behalf of [●] ("Holder"), as registered owner of this Purchase Warrant, to Tenon Medical, and among Professional Diversity Network, Inc., a Delaware corporation (the "Company"),
Holder, NAPW, Inc., and NAPW Merger Sub, Inc., Holder is entitled, at any time or from time to time
beginning [●], 2022 from September 24, 2015 (the "Commencement D
...ate"), and at or before 5:00 p.m., Eastern time, [●], 2026 September 24, 2019 (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] 131,250 shares of common stock of the Company, par value $0.00001 $.01 per share (the "Shares"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this the Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] $10.00 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context.
View More
Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of
[●] __________________ ("Holder"), as registered owner of this Purchase Warrant, to
Tenon Medical, Odyssey Group International, Inc., a
Delaware Nevada corporation (the "Company"), Holder is entitled, at any time or from time to time
beginning [●], 2022 from August 6, 2020 (the
"Commencement "Effective Date"), and at or before 5:00 p.m., Eastern time,
[●], 2026 August 6, 2024 (the "Expiration Date"), but not thereafter,
...to subscribe for, purchase and receive, in whole or in part, up to [●] 220,000 shares (the "Shares") of common stock of the Company, par value $0.00001 $0.001 per share (the "Shares"), "Common Stock"), subject to adjustment as provided in Section 6 hereof. The total Shares issuable pursuant to all Purchase Warrants is referred to herein as the "Warrant Shares." If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] $0.01 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context.
View More
Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of
[●] [·] ("Holder"), as registered owner of this Purchase Warrant, to
Tenon Medical, Akers Biosciences, Inc., a
Delaware New Jersey corporation (the "Company"), Holder is entitled, at any time or from time to time
beginning [●], 2022 from [_________], 2014 (the "Commencement Date"), and at or before 5:00 p.m., Eastern time,
[●], 2026 [___________], 2018 (the "Expiration Date"), but not thereafter, to subscribe for, purcha
...se and receive, in whole or in part, up to [●] [·] shares of common stock of the Company, Company [equal to 3% of the Shares sold in the Offering], par value $0.00001 $0.001 per share (the "Shares"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this the Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] $[___] per Share; Share (125% of the price of the Shares sold in the Offering); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context.
View More
Purchase Warrant. THIS CERTIFIES THAT,
in consideration for good and valuable consideration, the receipt and sufficiency of
funds duly paid by or on behalf of [●] which is hereby acknowledged, Roth Capital Partners, LLC ("Holder"), as registered owner of this Purchase Warrant,
to Tenon Medical, Inc., a Delaware corporation (the "Company"), Holder is entitled, at any time or from time to time
beginning [●], 2022 from [•], 2020 [DATE THAT IS ONE HUNDRED EIGHTY (180) DAYS FROM THE EFFECTIVE DATE OF THE OFFERING] (th
...e "Commencement Date"), and at or before 5:00 p.m., Eastern time, [●], 2026 [•], 2025 [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING] (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares [____] (the "Shares") of common stock of the Company, stock, par value $0.00001 $0.0001 per share (the "Shares"), "Common Stock"), of Myomo, Inc., a Delaware corporation (the "Company"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized or required by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] $7.00 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Purchase Warrant is being issued in connection with a public offering of shares of Common Stock pursuant to the Company's registration statement on Form S-1 (File No. : 333-235538) (the "Offering"). The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context. As used herein, "Effective Date" means the date on which the Shares being sold in the Offering first become legally eligible for distribution to the public as determined in accordance with FINRA Conduct Rule 5110(a)(12).
View More
Purchase Warrant. THIS CERTIFIES THAT,
in consideration of funds duly paid pursuant to that certain Placement Agency Agreement by
and between ADOMANI, Inc., a Delaware corporation (the "Company"), and Boustead Securities, LLC ("Boustead"), as placement agent, dated [●], 2017 (the "Placement Agency Agreement"), Boustead (in such capacity with its permitted successors or
on behalf of [●] ("Holder"), assigns, the "Holder"), as registered owner of this Purchase Warrant,
to Tenon Medical, Inc., a Delaware corporation ...(the "Company"), Holder is entitled, at any time or from time to time beginning from [●], 2022 20[__] (the "Commencement Date"), "Exercise Date") [THE DATE THAT IS THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT], and at or before 5:00 p.m., Eastern time, [●], 2026 20[ ] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING] (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of common stock of the Company, par value $0.00001 per share (the "Shares"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] per Share; Share [100.0% of the price of the Units sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Placement Agency Agreement.
View More
Purchase Warrant. THIS CERTIFIES THAT,
in consideration for good and valuable consideration, the receipt and sufficiency of
funds duly paid by or on behalf of [●] which is hereby acknowledged, Laidlaw & Co. (UK) Ltd., ("Holder"), as registered owner of this Purchase Warrant,
to Tenon Medical, Inc., a Delaware corporation (the "Company"), Holder is entitled, at any time or from time to time
beginning [●], 2022 from March 25, 2023 (the "Commencement Date"), and at or before 5:00 p.m., Eastern time,
[●], 2026 Septem...ber 26, 2027 (the "Expiration Date"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares 57,500 (the "Shares") of common stock of the Company, stock, par value $0.00001 $0.0001 per share (the "Shares"), "Common Stock"), of Silo Pharma, Inc., a Delaware corporation (the "Company"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized or required by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] $6.25 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Purchase Warrant is being issued in connection with a public offering of shares of Common Stock pursuant to the Company's registration statement on Form S-1 (File No. : 333-261532 (the "Offering"). The term "Exercise Price" shall mean the initial exercise price or the adjusted exercise price, depending on the context. As used herein, "Effective Date" means the date on which the Shares being sold in the Offering first become legally eligible for distribution to the public as determined in accordance with FINRA Conduct Rule 5110(a)(12).
View More
